

Formulary Update

March 2025

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since March 2025. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Cetraben ointment	Use on advice of gynaecology/dermatology specialists	13.2.2	Formulary change request
Fobumix Easyhaler	Additional device choice of combination inhaler for budesonide and formoterol fumarate	3.2.2	Formulary change request
Liothyronine capsules	New treatment choice, in addition to tablets, with currently a lower acquisition cost	6.2.1	Formulary change request
Melatonin	Acute and chronic sleep disorders in adult patients restricted to use according to secondary care input and new NHSGGC melatonin treatment guideline	4.1.1.1, 4.1.1.2	Formulary change request
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Budesonide/formoterol dry powder inhalers	Changed from Total Formulary to Preferred List	3.2.2	Formulary change request
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Eribulin	Brand name removed from formulary entry as product has been de-branded.	8.1.5	Change to product branding
Levonorgestrel 52mg IUDs	Insertion duration amended to 8 years for use as contraception according to updated product licences.	7.3.2.3	Change to product licencing